

Docket No. 47578

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
G. Durant et al.



Serial No.: 09/176,067

Examiner: P. O'Sullivan

Filed: October 20, 1998

Group Art Unit: 1621

For: PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

Applicants are in receipt of the Restriction Requirement dated March 27, 2000.

In response to the Restriction Requirement, Applicants elect Group I, directed to claims 1-6, 10, 11, 19-24 and 26-45, acylguanidines, methods and compositions.

For the Species election, Applicants elect:

a compound of N-(4-methylbenzoyl)-N'-(4-phenylbutyl) guanidine; and a method of treating nerve cell death or degeneration.

Applicants will also submit an Information Disclosure Statement under separate cover for this application.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

Peter R. Corless (Reg. No. 33,860)
Dike, Bronstein, Roberts & Cushman, LLP
130 Water Street
Boston, MA 02109
(617) 523-3400